Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nanatinostat SCHEMBL22712412 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Nanatinostat SCHEMBL29602260 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Nanatinostat SCHEMBL22712415 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Nanatinostat SCHEMBL22712419 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Nanatinostat SCHEMBL29453926 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Nanatinostat SCHEMBL25612092 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1010499 | 0.90 | HDAC1 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23510865 | 0.89 | HDAC3 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8242833 | 0.87 | HDAC1 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011927 | 0.87 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20260000672-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | VIRACTA SUBSIDIARY INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4650005-A2 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | Viracta Subsidiary, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| EP-3484478-B1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | VIRACTA SUBSIDIARY INC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12427152-B2 | HDAC inhibitors for use with NK cell based therapies | VIRACTA THERAPEUTICS, INC. (CA) | 2025-09-30 | — | — | US | claimed |
| EP-4596053-A2 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | Viracta Subsidiary, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-3484489-B1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA SUBSIDIARY INC (US) | 2025-06-18 | — | — | EP | claimed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-12083119-B2 | Methods and compositions for treating viral or virally-induced conditions | Viracta Subsidiary, Inc. (US) | 2024-09-10 | — | — | US | claimed |
| US-20190290646-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | INFINITY SA LLC, AS PURCHASER AGENT | 2019-09-26 | — | — | US | claimed |
| US-20190216818-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | VIRACTA THERAPEUTICS, INC. (US) | 2019-07-18 | — | — | US | claimed |
| EP-3484478-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | Viracta Therapeutics, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| EP-3484489-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | Viracta Therapeutics, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| WO-2018013975-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS, INC. (US) | 2018-01-18 | — | — | WO | claimed |
| WO-2018013962-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | VIRACTA THERAPEUTICS, INC. (US) | 2018-01-18 | — | — | WO | claimed |
| US-20130331313-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | TRUSTEES OF BOSTON UNIVERSITY | 2013-12-12 | — | — | US | claimed |
| US-20110245154-A1 | Methods and Compositions for Treating Viral or Virally-Induced Conditions | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2011113013-A2 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | HDAC9, HDAC4, HDAC5 | HDAC3 5/4885HDAC4 2/4885HDAC1 11/4885 |
| US-20260000672-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | HDAC7, HDAC8, HDAC9 | HDAC3 10/4885HDAC4 4/4885HDAC1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.